Update on Clinical Study Assessing Visco-ease for Treatment of Radiotherapy-Induced Xerostomia (RIX)

Bellshill, Glasgow, UK 12 May 2017- Lamellar Biomedical, a biotechnology company developing a range of patent-protected medical and pharmaceutical products, based on LAMELLASOMETM technology, provides an update on the results of the clinical study assessing the ability of Visco-ease to restore the function of saliva in patients undergoing radiotherapy for the treatment of Head and … Continued

Lamellar Biomedical Recruits First Patients into Clinical Study Assessing LAMELLEYE™ for Treatment of Dry Eye Disease

Bellshill, Glasgow, UK – 31 May 2017 – Lamellar Biomedical, a biotechnology company developing a range of patent-protected medical and pharmaceutical products, based on its LAMELLASOME™ technology, announces the recruitment of the first patients in a clinical study assessing LAMELLEYE for the treatment of moderate to severe Dry Eye Disease (DED). Moderate to severe DED … Continued

Lamellar Biomedical Raises £5.75m in Series C Fund Raising led by Invesco

Lamellar Biomedical, a biotechnology company developing a range of patent-protected medical and pharmaceutical products, based on LAMELLASOME™ technology, has raised £5.75 million in a Series C equity funding round. The financing was led by Invesco Asset Management Limited acting as agent for and on behalf of its discretionary managed clients (“Invesco”) and supported by the … Continued

Lamellar Biomedical Announces Completion of Patient Recruitment in the Pivotal Registration Clinical Study Assessing Visco-ease for the Treatment of Radiotherapy-Induced Xerostomia (RIX)

Lamellar Biomedical Announces Completion of Patient Recruitment  in the Pivotal Registration Clinical Study Assessing Visco-ease for the  Treatment of Radiotherapy-Induced Xerostomia (RIX) Bellshill, Glasgow, UK 6 December 2016 – Lamellar Biomedical, a biotechnology company developing a range of patent-protected medical and pharmaceutical products, based on LAMELLASOMETM technology, announces that patient recruitment has been completed in … Continued

Lamellar Biomedical and Beatson West of Scotland Cancer Centre Announce Recruitment of First Patient in Clinical Study

Lamellar Biomedical and the Beatson West of Scotland Cancer Centre Announce Recruitment of First Patient in Clinical Study Assessing Visco-ease for the Treatment of Radiotherapy-Induced Xerostomia (RIX) Bellshill, Glasgow, UK 29th March 2016 – Lamellar Biomedical, a biotechnology company developing a range of patent-protected medical and pharmaceutical products, based on Lamellasome™ technology, and the Beatson … Continued

Lamellar Biomedical Signs Agreement with Edinburgh Complex Fluids Partnership, University of Edinburgh

Lamellar Biomedical Signs Agreement with Edinburgh Complex Fluids Partnership, University of Edinburgh, to Advance Research into the Biophysical Properties of Lamellasomes Agreement will lead to new LamellasomeTM applications and IP  Lamellar Biomedical, a biotechnology company developing a range of patent-protected medical devices and pharmaceuticals, based on its unique Lamellasome™ technology, announces the signing of a … Continued

Lamellar Biomedical makes Pitch@Palace bid

Bellshill, Glasgow, 22nd February 2016 – Lamellar Biomedical, a biotechnology company developing a range of patent-protected medical and pharmaceutical products, based on Lamellasome™ technology, today competes in the secondary stage of Pitch@Palace, an event for biotech entrepreneurs, founded by The Duke of York. Biotech companies going forward into this next round of Pitch@Palace will be … Continued

Visco-ease Paper Published in Supportive Care Journal

Visco-ease Paper Published in Supportive Care Journal Data published from a positive pre-clinical study with Visco-ease (LMS-611) showing it can restore the functionality of the saliva of patients undergoing radiotherapy for Head & Neck Cancer Bellshill, Glasgow, 2nd February 2016 – Lamellar Biomedical, a biotechnology company developing a range of patent-protected medical devices and pharmaceuticals, … Continued

Lamellar to present at BIO-Europe 2015

Lamellar to present at BIO-Europe 2015 Bellshill, Glasgow, 29th October 2015 – Lamellar Biomedical, a biotechnology company developing a range of patent-protected medical devices and pharmaceuticals, based on LamellasomeTM technology, that enables the creation of mimetics of extra-alveolar lamellar bodies, announces that its CEO Dr Alec McLean is to present at BIO-Europe 2015 in Munich. … Continued

Lamellar Biomedical Closes £2.3 million Investment Round

Lamellar Biomedical Closes £2.3 million Investment Round Bellshill, Glasgow, 24th July, 2015 Lamellar Biomedical, a privately held Scottish biotechnology company, has closed a £2.33 million equity capital investment round subscribed entirely by existing Shareholders. The round comprised a Rights Issue, which was oversubscribed, together with exercise of Warrants held by certain Shareholders. Participating investors included … Continued